Madrigal Pharmaceuticals Q4 EPS $(5.68) Misses $(5.28) Estimate; Cash, Cash Equivalents And Marketable Securities Of $634M
Portfolio Pulse from Benzinga Newsdesk
Madrigal Pharmaceuticals reported a Q4 EPS loss of $(5.68), missing the consensus estimate of $(5.28) by 7.58%. This represents a 14.06% increase in losses compared to the same period last year. The company also reported having $634M in cash, cash equivalents, and marketable securities.
February 28, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Madrigal Pharmaceuticals reported a larger-than-expected Q4 loss and an increase in losses from the previous year, but maintains $634M in liquidity.
The reported earnings miss and increased losses year-over-year are likely to negatively impact investor sentiment in the short term. However, the substantial cash reserves may provide some cushion against negative market reactions.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100